Welcome to our dedicated page for PROTHENA PUBLIC CO SEC filings (Ticker: PRTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PROTHENA PUBLIC CO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PROTHENA PUBLIC CO's regulatory disclosures and financial reporting.
PROTHENA CORP PUBLIC LTD CO reported that Chief Development Officer Chad J. Swanson acquired a grant of 190,000 stock options on March 3, 2026. The options were awarded at no cost as a “Stock Option (Right to Buy).”
According to the vesting terms, 25% of the total options will vest and become exercisable on March 3, 2027. The remaining options will vest in equal monthly installments of 1/48th of the total number of shares on each monthly anniversary thereafter, subject to his continued employment with the company on each vesting date.
PROTHENA CORP PUBLIC LTD CO granted Chief Operating Officer Brandon S. Smith a stock option covering 190,000 shares on March 3, 2026. This option was reported as a direct, derivative security and classified as a grant or award acquisition.
According to the vesting terms, 25% of the shares underlying the option will vest and become exercisable on March 3, 2027. The remaining shares will vest in 1/48th monthly installments on each monthly anniversary thereafter, conditioned on Smith’s continued employment with the company on each vesting date.
Nguyen Tran reported acquisition or exercise transactions in this Form 4 filing.
PROTHENA CORP PUBLIC LTD CO granted Nguyen Tran, its Chief Strategy Officer and CFO, a stock option covering 230,000 shares. The option vests as to 25% of the shares on March 3, 2027, with the remaining 75% vesting in equal monthly installments over the following three years, subject to continued employment.
Malecek Michael J reported acquisition or exercise transactions in this Form 4 filing.
Prothena Corp Public Ltd Co granted Chief Legal Officer Michael J. Malecek a stock option covering 190,000 shares of the company’s stock. According to the award terms, 25% of the option will vest and become exercisable on March 3, 2027. The remaining shares will vest in equal monthly installments of 1/48th of the total option on each monthly anniversary thereafter, subject to his continued employment with the company on each vesting date.
Kinney Gene G. reported acquisition or exercise transactions in this Form 4 filing.
PROTHENA CORP PUBLIC LTD CO reported that President and CEO Gene G. Kinney received a grant of stock options covering 520,000 shares on March 3, 2026. These options vest as to 25% of the total shares on March 3, 2027, then in equal monthly installments of 1/48th of the total shares on each monthly anniversary thereafter, subject to his continued employment with the company.
Prothena Corporation plc announced that its board has authorized a share repurchase plan allowing the company to buy back up to $100.0 million of its outstanding ordinary shares. The plan runs through December 31, 2026, is fully discretionary, and can be suspended or ended at any time.
Prothena reported $308.4 million in cash, cash equivalents and restricted cash and no debt as of December 31, 2025, and expects to end 2026 with about $255 million in cash excluding any repurchases. The company also highlights potential to earn up to $105 million in 2026 clinical milestone payments from strategic partners Novo Nordisk and Bristol Myers Squibb.
Prothena Corporation plc amends its S-3 shelf to register up to $200,000,000 of ordinary shares for issuance from time to time after the registration statement is effective. This post-effective amendment also states the company is no longer a well-known seasoned issuer.
Each future issuance will be described in a prospectus supplement that sets amounts, prices and terms. The filing discloses issued ordinary shares of 53,832,982 as of December 31, 2025 as a context figure.
Prothena Corporation plc filed its annual report describing a late-stage biotechnology company focused on diseases caused by protein misfolding, particularly neurodegenerative and rare amyloid disorders. Its pipeline spans wholly owned and partnered antibody, small‑molecule and vaccine programs.
Key partnered assets include prasinezumab with Roche for Parkinson’s disease, coramitug with Novo Nordisk for ATTR cardiomyopathy, and BMS-986446 and PRX019 with Bristol Myers Squibb for Alzheimer’s and other neurodegenerative diseases. Early programs feature the CYTOPE® intracellular targeting platform, Alzheimer’s candidates PRX012 and PRX012‑TfR, and dual Aβ‑tau vaccine PRX123.
The company discontinued development of birtamimab after the Phase 3 AFFIRM‑AL trial failed to meet its endpoints and implemented an approximate 63% workforce reduction in 2025 to lower operating costs while continuing to support key collaborations and selected wholly owned projects.
Prothena Corporation plc amends its shelf registration to permit the offer and issuance of up to $200,000,000 of ordinary shares from time to time. This Post-Effective Amendment notes the company will no longer qualify as a well-known seasoned issuer after filing its Annual Report for the year ended December 31, 2025.
The prospectus describes the general terms for future takedowns under the shelf, the requirement that each offering be accompanied by a prospectus supplement with specific amounts, prices and terms, and that offerings may be conducted through underwriters, dealers, agents or directly to purchasers.
Prothena Corporation plc reported significantly weaker 2025 financial results while highlighting progress across its partnered neurology pipeline. For 2025, the company posted a net loss of $244.1 million, nearly double the prior year’s $122.3 million, as revenue fell to $9.7 million from $135.2 million driven by lower collaboration payments.
Research and development expenses declined to $134.9 million and general and administrative expenses to $59.4 million, reflecting lower clinical, personnel, manufacturing, and consulting costs, though results included $30.1 million of restructuring charges and a $43.2 million non-cash tax expense. Prothena ended 2025 with $308.4 million in cash, cash equivalents and restricted cash and no debt, and had about 53.8 million ordinary shares outstanding as of February 12, 2026.
For 2026, Prothena expects net cash used in operating and investing activities of $50–$55 million and to finish the year with roughly $255 million in cash at the midpoint, excluding up to $105 million of potential clinical milestone receipts from partners. The company also secured shareholder and court approval to create distributable reserves, allowing its board to consider a share redemption program in 2026 at its discretion, and noted multiple late-stage trials with Roche, Novo Nordisk, and Bristol Myers Squibb targeting Parkinson’s, ATTR amyloidosis, and Alzheimer’s disease.